RECEIVED CENTRAL FAX CENTER

T-628 P.001

F-747

Customer No. 28880

FEB 2 7 2006

Confirmation No. 5646

Date

February 27, 2006

PTO/SB/21 (09-04) Approved for use through 07/31/2008. OMB 0551-0031

Approved for use through 07/31/2008. OMB 0551-0031

U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Progress Reduction Act of 1995, no cersons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Absolute. Application Number 09/868,120 Filing Date TRANSMITTAL June 14, 2001 First Named Inventor David Thomas Dudley FORM Art Unit 1617 Examiner Name San Ming R. Hui (to be used for all correspondence after initial filing) Attorney Docket Number 5968-01-CFP Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers of Appeals and Interferences Fee Attached Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Petition Amendment/Reply Petition to Convert to a Proprietary Information Provisional Application After Final Power of Attorney, Revocation Status Letter Change of Correspondence Address Affidavits/declaration(\$) Other Enclosure(s) (please Identify Terminal Disclaimer below): Extension of Time Request Information Disclosure Statement Request for Refund Express Abandonment Request Under 37 CFR 1.97(c)(1) Supplemental CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Warner-Lambert Company LLC Signature Printed name Claude F. Purchase, Jr. Reg. No. Date 47,871 February 27, 2006 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: index Mriocha Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time with vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradement Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissionor for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

USPTO Fax No.

Typed or printed name

571-273-8300

RECEIVED CENTRAL FAX CENTER

T-628 P.002 F-747

FEB 2 7 2006

09/868,120

5968-01-CFP

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICATION NO.

09/868,120

Confirmation No.:

5646

APPLICANT(S)

David Thomas Dudley, et al.

FILED

June 14, 2001

ART UNIT

1617

EXAMINER

San Ming R. Hui

DOCKET NO.

5968-01-CFP (PC17525)

CUSTOMER NO.

28880

Mail Stop Amendment Commissioner for Patents PO BOX 1450 Alexandria, VA 22313-1450 FAX: (571) 273-8300

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)(1)

Dear Sir:

Applicants make available to the Patent and Trademark Office a supplemental information disclosure statement on form PTO/SB/08B. The item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Applicants believe no fee is required. However, the Commissioner is hereby authorized to charge any fees that may be required, or credit any overpayment, to deposit account number 23-0455.

Applicants respectfully request that the Examiner consider carefully the complete text of the cited reference(s) in connection with the continued examination of the above-identified application in accord with 37 CFR §1.104(a).

It is respectfully requested that all cited reference(s) considered by the Examiner be listed in the "References Cited" portion of any patent issuing from the instant application (MPEP § 1302.12).

09/868,120

5968-01-CFP

Respectfully submitted,

Date: February 27, 2006

Claude F. Purchase, Jr.

Reg. No. 47,871

Pfizer Inc.

2800 Plymouth Road Ann Arbor, MI 48105 Tel. (734) 622-1692

Fax (734) 622-1553

RECEIVED CENTRAL FAX CENTER

Feb-27-2006 10:00am

P.004/011 F-747 T-628

FEB 2 7 2006

1

of

Customer No. 28880

Sheet

Examiner

Signature

Confirmation No. 5646

DIL INU. 3040 PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete If Known Substitute for form 1449/PTO **Application Number** 09/868,120 SUPPLEMENTAL Filing Date INFORMATION DISCLOSURE June 14, 2001 STATEMENT BY APPLICANT First Named Inventor David Thomas Dudley Art Unit 1617 (Use as many sheets as necessary) Examiner Name San Ming R. Hui

Attorney Docket Number

5968-01-CFP

Examiner Initials*	Cite No. ¹	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		WILLIAMS et al., "Ro 09 2210 Exhibits Potent Anti-proliferative Effects on Activated T Cells by Selectively Blocking MKK Activity", Biochemistry, Vol. 37, No. 26, 1998, pp 9579-9585	
		·	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

considered. Include copy of this form with flexic communication to applicants.

Applicant's unique citation designation number (optional), 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, inducting gathering, preparing, and submitting the complete application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.